VM:CC - Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast

(TheNewswire)

Calgary, Canada, May 28, 2024 – TheNewswire – Voyageur Pharmaceuticals Ltd . (TSX.V: VM)(USA: VYYRF) ("Voyageur" or the "Company") proudlyannounces its first international distribution agreement with a salescommitment of USD $1.9million ( CAD $2.6M ), over the first three (3) years ofcommercialization. The agreement is with a company specializing in thesale of radiology products in Latin America. This initial agreementgrants the distributor marketing and sales rights in two countries,for SmoothX 2%, a contrast medium for use in abdominal ComputedTomography (CT) diagnostic examinations.

The distributor will assume the costs andresponsibility for product regulatory approvals and commercializationin the territory, allowing Voyageur to introduce SmoothX in LatinAmerica. This marks the beginning of Voyageur’s expansion intointernational markets and paves the way for the introduction of itsfull suite of barium sulfate contrast medium products for medicalimaging.  Product pricing is based on volume milestones.

Due to the highly competitive landscape of amonopolised barium contrast industry, additional contract details areconfidential. The estimated contract value has been determined basedon management's expectations with respect to sales volumes during theterm of the contract.

Voyageur has four additional products at late stages ofdevelopment:

• Vision HD® 98%: high-density (98% w/w) barium sulfate powder for upper GIdouble-contrast radiographic examinations.

• Vision LD® 96%: versatile high-density (57% w/w to 156% w/w) barium sulfatepowder for single contrast radiographic examinations of the upper andlower GI tract.

• Smooth HD® 105%: high-density (105% w/v, 58% w/w) barium sulfate suspension for upper GIesophagogram and double contrast studies

• Smooth LD® 60%: low-density (60% w/v) barium sulfate suspension solution forsingle contrast radiographic examinations of the esophagus, stomach,and small bowel.

Voyageur remains steadfast in its commitment toproviding solutions to the medical imaging market. With the impendingcompletion of the development of these products, the Company is poisedto offer a comprehensive suite of diagnosticsolutions to meet the diverse needs of healthcare professionalsworldwide.

Starting with its barium contrast media product line,Voyageur’s strategy is to systematically introduce a comprehensivesuite of imaging products, set to diversify the medical imaginglandscape in the Canadian and international markets.  Additionally,to facilitate the introduction of its innovative products, the companyplans to expand into the U.S. market, leveraging the success andregulatory approvals in other countries.

For further details on Voyageur's innovative productofferings and to secure pre-market orders, please visit our officialwebsite at https://voyageurpharmaceuticals.ca .

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium and iodine ActivePharmaceutical Ingredients (API) and offers high-performance,cost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium and iodine contrast market, Voyageuraims to become a key player by producing its own barium, iodine, andfullerene minerals.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As Voyageur solidifies its presence inthe market, it plans to transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.

Voyageur is committed to sustainability andenvironmental stewardship. Voyageur envisions a future where carbonneutrality is the norm, and to achieve this, it is buildingstate-of-the-art carbon-neutral infrastructure utilising the Rain Cage EDEN TM system . Byinvesting in carbon neutral energy sources and sustainablemanufacturing practices, Voyageur aims to increase revenue from carboncapture to accelerate growth. Voyageur's unwavering commitment to theenvironment sets it apart as a pioneer in the industry.

At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project. Thisproject boasts exceptional grade minerals suitable for thepharmaceutical marketplace.

Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the radiologycontrast media drug market. By controlling all primary input costs,from the sourcing of raw materials to the final production, Voyageurensures quality and cost efficiency. With its approach, it embodiesthe motto of " From theEarth to the Bottle ," highlightingVoyageur's commitment to responsible sourcing and manufacturingpractices.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

Thisnews release may contain certain forward-looking information andstatements, including without limitation, statements pertaining to:the realizable value to Voyageur from the sales contract; theexpectation that Voyageur will obtain drug license approvals; marketacceptance and sales for the suite of five new licensed products andSmoothX; the successful completion of the clinical testing for theremaining four products; the Rain Cage EDENTM technology being carbonneutral; and availability of financing. All statements includedherein, other than statements of historical fact, are forward-lookinginformation and such information involves various risks anduncertainties. There can be no assurance that such information willprove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR+ website atwww.sedarplus.ca. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.

Copyright (c) 2024 TheNewswire - All rights reserved.